
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc. has experienced substantial stock appreciation of nearly 90% in the last month, highlighting a growing market confidence in its multi-cancer early detection technologies. The company's proprietary Total Addressable Market (TAM) analysis indicates a significant opportunity valued at approximately $3.7 billion in the UK by 2026, with potential growth to $4.0 billion by 2035, further bolstered by strategic partnerships to capture this market. Despite existing uncertainties around regulatory approvals and Medicare reimbursement, the positive data from the PATHFINDER 2 ESMO trial and a robust $400 million pending addition to GRAIL's balance sheet contribute to a favorable outlook for the company.
Bears say
GRAIL Inc has consistently reported substantial net losses since its inception, with expectations of ongoing losses as the company invests in studies, regulatory approvals, and expanding infrastructure. The firm faces significant risks that could impede its growth, including legislative delays obstructing reimbursement pathways, adoption challenges for its novel testing technology, and intense competition from established diagnostics companies with greater resources. Additionally, the anticipated increase in selling, general, and administrative expenses tied to Galleri volume growth, coupled with potential setbacks in clinical study timelines and financing challenges, further dampens the outlook for the company's operational and commercialization capabilities.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares